Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.
Authors
- Silke Buda (ORCID: https://orcid.org/0000-0003-3448-3357)
- Kristin Tolksdorf (ORCID: https://orcid.org/0000-0002-8712-6399)
- Barbara Biere (ORCID: https://orcid.org/0000-0001-6988-3735)
- Marianne Wedde
- Ralf Dürrwald (ORCID: https://orcid.org/0000-0002-3432-0438)
- Ute Preuß
- Carolin Hackmann (ORCID: https://orcid.org/0000-0001-8788-3632)
- Janine Reiche (ORCID: https://orcid.org/0000-0003-2541-1095)
- Annika Erdwiens
Institutions
- Robert Koch Institute (DE)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1111/irv.70115
- Citations
- 3
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- HELIOS Kliniken
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- European Centre for Disease Prevention and Control
- Bundesministerium für Gesundheit
- Robert Koch Institut